Summary
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
History
First Wave Biopharma was founded in 2020 with the goal of developing drugs for serious diseases and improving patient access to quality drug treatments. Since then, the company has grown significantly and now employs over 300 scientists and researchers working on the latest advances in biopharmaceuticals. We are proud to have established relationships with leading healthcare organizations and to be at the forefront of developing innovative treatments.
Mission
At First Wave Biopharma, we strive to be a leader in biopharmaceuticals. We are committed to developing innovative treatments that extend and enhance patient lives while providing personalized care. Our research is centered on delivering best-in-class customer experience, offering access to quality drugs, and partnering with leading healthcare organizations.
Vision
Our vision is to be the leader in biopharmaceuticals and the drug of choice for serious diseases. We are committed to providing the highest quality of care and treatments, working together with patients and their families to develop a more comprehensive understanding of their illnesses.
Key Team
Ms. Sarah Romano CPA (Chief Financial Officer)
Ms. Amy Chandler-Skerkis (VP of Regulatory Affairs, QA & Compliance)
Recognition and Awards
First Wave Biopharma has been honored with numerous awards for its innovative treatments and dedication to patient access to quality drug treatments. Our company has won the Health Care Innovator of the Year Award from the Healthcare Business Association and the Discovery of the Year Award from the Drug Development Forum.
References
